Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus

• Main Authors: Shohreh Shahabi, Ilenia Pellicciotta, June Hou, Sarah Graceffa, Gloria S. Huang, Robert N. Samuelson, Gary L. Goldberg
• Format: Article
• Language: English
• Published: SAGE Publishing 2011-10-01
• Series: Rare Tumors
• Subjects: Large cell neuroendocrine carcinoma, uterine corpus, chromogranin A, octerotide
• Online Access: http://www.pagepress.org/journals/index.php/rt/article/view/3237
• ISSN: 2036-3605; 2036-3613

Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix, consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.